Fructose emerges as a metastasis signal in chemotherapy-surviving ovarian cancer
A common sugar may be doing more than sweetening drinks and desserts. In aggressive ovarian cancer, fructose appears to help chemotherapy-surviving cells send a metabolic signal that loosens neighboring tumor cells and makes spread easier in preclinical models.
The work, published in Nature Aging, centers on a striking idea: cells that are no longer dividing after platinum-based chemotherapy can still shape the behavior of the tumor around them. Those surviving cells release molecules, and among them fructose stood out as a driver of detachment and dissemination. In practical terms, a tumor does not need every cell to keep multiplying in order to remain dangerous; a residual population can continue to remodel the microenvironment and encourage metastasis.
Aidan Cole, Ph.D., a postdoctoral fellow in Katherine Aird’s lab at The Wistar Institute and first author of the study, said the team found that these nondividing cells remain biologically active and continue to release signals. Fructose was one of those signals. The finding matters because it reframes chemotherapy survival from a passive state to an active source of metastatic instruction.
Surviving cells kept signaling even after chemotherapy stopped proliferation
Most ovarian cancers are treated with platinum-based chemotherapy, which damages DNA and suppresses replication. Initial responses are common, but recurrence is frequent, and spread within the abdominal cavity drives most deaths from the disease. The study was built around that clinical pattern: tumors often shrink, yet microscopic remnants return with renewed ability to invade nearby tissue and seed distant sites inside the abdomen.
To separate the effect of surviving cells from the material they release, investigators designed experiments that isolated the secreted products from the cells themselves. Those released molecules, even without the cells present, were enough to increase cancer spread in a preclinical model. Cole described that result as the first demonstration, in a preclinical model rather than only in cell culture, that the secreted molecules—not merely the surviving cells—can drive dissemination.
One sentence captures the shift: the tumor’s surviving fraction did not stay quiet.
Fructose reduced cholesterol production and weakened cell-to-cell bonds
The next step was identifying which molecule in the secreted mixture carried the signal. Fructose emerged as the key candidate. It is naturally present in fruit and honey, and it also appears in table sugar and high fructose corn syrup, a common sweetener in soft drinks and processed foods.
In the experiments, chemotherapy-surviving cancer cells produced fructose and released it into their surroundings. The sugar did not act merely as fuel. It functioned as a chemical messenger that altered the behavior of neighboring tumor cells, pushing them toward a more mobile state.
Mechanistically, the work tied that effect to cholesterol metabolism. Fructose suppressed cholesterol production in nearby cancer cells. Cholesterol is best known for its role in cardiovascular disease, but in this context it helped preserve cell membrane structures and the adhesive connections that keep neighboring cells attached. When cholesterol synthesis fell, those junctions weakened. Cells detached more readily, and detachment is a prerequisite for invasion and metastasis.
The biology is straightforward and unsettling: less cholesterol, weaker cellular adhesion, easier escape.
High-fructose exposure changed metastatic signals even without chemotherapy
The study also examined what happened when animals were exposed to high amounts of fructose comparable to those found in sugary drinks. Under those conditions, signals associated with cancer spread increased even without chemotherapy. That result raises the possibility that dietary fructose may influence tumor behavior through a pathway that had not previously been recognized in this setting.
The work does not establish that sugar intake causes ovarian cancer to spread in patients, and it does not justify dietary prescriptions based on this mechanism alone. Even so, the finding places a familiar nutrient into a very different biological context. Fructose intake is modifiable, which makes it a plausible target for future study, but the clinical value of reducing it remains untested in patients with ovarian cancer.
For now, the evidence stays where it belongs: in the preclinical domain, where mechanism can be mapped before outcome claims are made.
Statins showed a similar effect on tumor-cell adhesion
The cholesterol connection led the investigators to an unexpected question about statins. These widely prescribed medications lower cholesterol synthesis, and the team asked whether they might mimic the same adhesion-lowering effect seen with fructose. In the preclinical experiments, statins alone weakened the connections between cancer cells and made separation easier.
That result does not mean statins should be stopped. It does mean the relationship between cholesterol-lowering therapy and chemotherapy response deserves closer scrutiny in ovarian cancer, especially in postmenopausal women who are frequently already receiving statins for cardiovascular risk reduction. Katherine Aird, Ph.D., professor and co-leader of the Molecular and Cellular Oncogenesis Program in the Ellen and Ronald Caplan Cancer Center at The Wistar Institute and senior author of the study, said the team has not tested the effect in patients and is now asking whether cholesterol-lowering drugs should be considered differently alongside chemotherapy.
The bedside implication is narrow but important: a medication class routinely used for heart protection may intersect with cancer biology in ways that were not anticipated.
The signal may extend beyond ovarian cancer
Although the experiments focused on ovarian cancer, the investigators suspect the same process could operate in other tumors that spread within the torso, including pancreatic, colon, and liver cancers. Those are biologically plausible candidates because their metastatic patterns often depend on local invasion, tissue detachment, and movement across nearby surfaces or organs.
Aird said the team is already designing experiments to test whether the mechanism reproduces in those cancer types. If it does, the work could extend beyond one disease into a broader principle of metastatic biology: residual treatment-resistant cells may reprogram their neighbors through metabolic cues, not just growth factors or inflammatory mediators.
The study’s immediate strength is mechanistic, not clinical. It identifies fructose as a signal that helps ovarian cancer cells break free, and it links that process to cholesterol suppression and cell adhesion. What remains unresolved is whether limiting fructose intake, changing statin use, or targeting this pathway directly will alter outcomes in patients. Those answers will require human studies, not only preclinical models.